Drug Profile
Teverelix
Alternative Names: EP-24332; Teverelix ER; Teverelix IR; Teverelix LA; Teverelix SRLatest Information Update: 05 May 2011
Price :
$50
*
At a glance
- Originator Zentaris
- Developer Ardana plc
- Class Acetic acids; Amides; Amines; Antihormones; Antineoplastics; Chlorobenzenes; Naphthalenes; Phenols; Pyridines; Pyrrolidines
- Mechanism of Action Gonadotropin releasing hormone inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Endometriosis; Prostate cancer
- Discontinued Female infertility; Pregnancy; Uterine leiomyoma
Most Recent Events
- 05 May 2011 No development reported - Phase-I for Endometriosis in United Kingdom (SC)
- 05 May 2011 No development reported - Phase-II for Benign prostatic hyperplasia in United Kingdom (SC)
- 05 May 2011 No development reported - Phase-II for Prostate cancer in United Kingdom (IM)